Jessica Wenthe

Tumor Microenvironment Gene Engineering with LOAd703 in Patients with Solid Malignancies: LOKON002 Phase I/IIb Clinical Trial

Hahn, Amanda; Irenaeus, Sandra; Sandin, Linda C.; Nordström, Clara et al.

Part of Clinical Cancer Research, p. 3157-3168, 2026

• DOI for Tumor Microenvironment Gene Engineering with LOAd703 in Patients with Solid Malignancies: LOKON002 Phase I/IIb Clinical Trial

CD40 stimulation via CD40 ligand enhances adenovirus-mediated tumour immunogenicity including 'find-me', 'eat-me', and 'kill-me' signalling

Naseri, Sedigheh; Mejia Cordova, Mariela; Wenthe, Jessica; Lövgren, Tanja et al.

Part of Journal of Cellular and Molecular Medicine, 2024

• DOI for CD40 stimulation via CD40 ligand enhances adenovirus-mediated tumour immunogenicity including 'find-me', 'eat-me', and 'kill-me' signalling
• Download full text (pdf) of CD40 stimulation via CD40 ligand enhances adenovirus-mediated tumour immunogenicity including 'find-me', 'eat-me', and 'kill-me' signalling

LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001) results from arm 1 of a non-randomised, single-centre, phase 1/2 study

Musher, Benjamin L.; Rowinsky, Eric K.; Smaglo, Brandon G.; Abidi, Wasif et al.

Part of The Lancet Oncology, p. 488-500, 2024

• DOI for LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001) results from arm 1 of a non-randomised, single-centre, phase 1/2 study

Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models

Wenthe, Jessica; Eriksson, Emma; Hellström, Ann-Charlotte; Moreno, Rafael et al.

Part of Journal of Translational Medicine, 2023

• DOI for Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models
• Download full text (pdf) of Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models

Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition

Wenthe, Jessica; Naseri, Sedigheh; Hellström, Ann-Charlotte; Moreno, Rafael et al.

Part of MOLECULAR THERAPY-ONCOLYTICS, p. 429-442, 2022

• DOI for Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition
• Download full text (pdf) of Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition

Tumor Microenvironment Gene Engineering with LOAd703 in Patients with Solid Malignancies: LOKON002 Phase I/IIb Clinical Trial

Hahn, Amanda; Irenaeus, Sandra; Sandin, Linda C.; Nordström, Clara et al.

Part of Clinical Cancer Research, p. 3157-3168, 2026

• DOI for Tumor Microenvironment Gene Engineering with LOAd703 in Patients with Solid Malignancies: LOKON002 Phase I/IIb Clinical Trial

CD40 stimulation via CD40 ligand enhances adenovirus-mediated tumour immunogenicity including 'find-me', 'eat-me', and 'kill-me' signalling

Naseri, Sedigheh; Mejia Cordova, Mariela; Wenthe, Jessica; Lövgren, Tanja et al.

Part of Journal of Cellular and Molecular Medicine, 2024

• DOI for CD40 stimulation via CD40 ligand enhances adenovirus-mediated tumour immunogenicity including 'find-me', 'eat-me', and 'kill-me' signalling
• Download full text (pdf) of CD40 stimulation via CD40 ligand enhances adenovirus-mediated tumour immunogenicity including 'find-me', 'eat-me', and 'kill-me' signalling

LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001) results from arm 1 of a non-randomised, single-centre, phase 1/2 study

Musher, Benjamin L.; Rowinsky, Eric K.; Smaglo, Brandon G.; Abidi, Wasif et al.

Part of The Lancet Oncology, p. 488-500, 2024

• DOI for LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001) results from arm 1 of a non-randomised, single-centre, phase 1/2 study

Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models

Wenthe, Jessica; Eriksson, Emma; Hellström, Ann-Charlotte; Moreno, Rafael et al.

Part of Journal of Translational Medicine, 2023

• DOI for Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models
• Download full text (pdf) of Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models

Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition

Wenthe, Jessica; Naseri, Sedigheh; Hellström, Ann-Charlotte; Moreno, Rafael et al.

Part of MOLECULAR THERAPY-ONCOLYTICS, p. 429-442, 2022

• DOI for Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition
• Download full text (pdf) of Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition

Systemic immunity upon local oncolytic virotherapy armed with immunostimulatory genes may be supported by tumor-derived exosomes

Labani-Motlagh, Alireza; Naseri, Sedigheh; Wenthe, Jessica; Eriksson, Emma et al.

Part of MOLECULAR THERAPY-ONCOLYTICS, p. 508-518, 2021

• DOI for Systemic immunity upon local oncolytic virotherapy armed with immunostimulatory genes may be supported by tumor-derived exosomes
• Download full text (pdf) of Systemic immunity upon local oncolytic virotherapy armed with immunostimulatory genes may be supported by tumor-derived exosomes

Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy

Wenthe, Jessica; Naseri, Sedigheh; Labani-Motlagh, Alireza; Enblad, Gunilla et al.

Part of Cancer Immunology and Immunotherapy, p. 2851-2865, 2021

• DOI for Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy
• Download full text (pdf) of Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy

Intratumoral immunostimulatory AdCD40L gene therapy in patients with advanced solid tumors.

Irenaeus, Sandra; Hellström, Vivan; Wenthe, Jessica; Krause, Johan et al.

Part of Cancer Gene Therapy, p. 1188-1197, 2021

• DOI for Intratumoral immunostimulatory AdCD40L gene therapy in patients with advanced solid tumors.

Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40

Wenthe, Jessica; Naseri, Sedigheh; Hellström, Ann-Charlotte; Jernberg Wiklund, Helena et al.

Part of Cancer Gene Therapy, p. 948-959, 2020

• DOI for Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40
• Download full text (pdf) of Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40

IL-6 Signaling Blockade during CD40-Mediated Immune Activation Favors Antitumor Factors by Reducing TGF-beta, Collagen Type I, and PD-L1/PD-1

Eriksson, Emma; Milenova, Ioanna; Wenthe, Jessica; Moreno, Rafael et al.

Part of Journal of Immunology, p. 787-798, 2019

• DOI for IL-6 Signaling Blockade during CD40-Mediated Immune Activation Favors Antitumor Factors by Reducing TGF-beta, Collagen Type I, and PD-L1/PD-1

A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia

Enblad, Gunilla; Karlsson, Hannah; Gammelgård, Gustav; Wenthe, Jessica et al.

Part of Clinical Cancer Research, p. 6185-6194, 2018

• DOI for A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia

Immunostimulatory gene therapy enhances PD-1 blockade antibody therapy in experimental lung cancer

Wenthe, Jessica; Eriksson, Emma; Hellström, Ann-Charlotte; Loskog, Angelica S.

Part of CANCER IMMUNOLOGY RESEARCH, 2018

• DOI for Immunostimulatory gene therapy enhances PD-1 blockade antibody therapy in experimental lung cancer

Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients

Schiza, Aglaia; Wenthe, Jessica; Mangsbo, Sara; Svensson, Emma et al.

Part of Journal of Translational Medicine, 2017

• DOI for Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients
• Download full text (pdf) of Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients

Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients

Irenaeus, Sandra; Schiza, Aglaia; Mangsbo, Sara M.; Wenthe, Jessica et al.

Part of Oncotarget, p. 78573-78587, 2017

• DOI for Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients
• Download full text (pdf) of Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients

Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus.

Svensson, Emma; Milenova, Ioanna; Wenthe, Jessica; Ståhle, Magnus et al.

Part of Clinical Cancer Research, p. 5846-5857, 2017

• DOI for Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus.

An oncolytic virus targeting desmoplasia and immune activation in pancreatic cancer

Eriksson, Emma; Milenova, Ioanna; Wenthe, Jessica; Moreno, Rafael et al.

Part of Scandinavian Journal of Immunology, p. 335-335, 2017

Distinct phenotype of CD19-specific CAR T cells generated from healthy donor vs. patient lymphocytes using either IL-7/IL-15 or IL-2

Hoffmann, J. -M; Stock, S.; Sellner, L.; Hueckelhoven, A. et al.

Part of Oncology Research and Treatment, p. 213-213, 2017

Adenovirus-mediated CD40L gene transfer increases teffector/tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients

Schiza, Aglaia; Wenthe, Jessica; Mangsbo, Sara; Eriksson, Emma et al.

Part of Scandinavian Journal of Immunology, p. 337-337, 2017

Immunological biomarkers correlate to survival in CAR19-treated patients

Lövgren, Tanja; Wenthe, Jessica; Karlsson, S. C. Hannah; Gammelgård, Gustav et al.

Part of Scandinavian Journal of Immunology, p. 337-337, 2017

Activating CD40 While Inhibiting IL6R Induces Cytokine Production without PDL1 Upregulation in DCs

Eriksson, Emma; Milenova, Ioanna; Wenthe, Jessica; Moreno, Rafael et al.

Part of Molecular Therapy, p. 54-54, 2017

Gemcitabine reduces MDSCs, tregs and TGF beta-1 while restoring the teff/treg ratio in patients with pancreatic cancer

Eriksson, Emma; Wenthe, Jessica; Irenaeus, Sandra; Loskog, Angelica et al.

Part of Journal of Translational Medicine, 2016

• DOI for Gemcitabine reduces MDSCs, tregs and TGF beta-1 while restoring the teff/treg ratio in patients with pancreatic cancer
• Download full text (pdf) of Gemcitabine reduces MDSCs, tregs and TGF beta-1 while restoring the teff/treg ratio in patients with pancreatic cancer

A Novel Oncolytic Adenovirus Expressing Tumor Microenvironment Stimulators to Evoke and Facilitate Anti-Tumor Immune Responses

Wenthe, Jessica; Eriksson, Emma; Milenova, Ioanna; Moreno, Rafael et al.

Part of Molecular Therapy, 2016

T cell stimulation with different cytokines results in distinct phenotypes and cytotoxic activity of CD19-specific CART cells

Hoffmann, J. -M; Gern, U.; Wang, L.; Kleist, C. et al.

Part of Oncology Research and Treatment, p. 136-136, 2016

• DOI for T cell stimulation with different cytokines results in distinct phenotypes and cytotoxic activity of CD19-specific CART cells

A Clinical Trial Using Third Generation CD19 Targeting CAR T Cells for Relapsed Lymphoma and Leukemia

Enblad, Gunilla; Karlsson, Hannah; Wenthe, Jessica; Wikström, Kristina I. et al.

Part of Molecular Therapy, 2016

CD40L and 4-1BBL immunostimulating gene therapy reduces myeloid-derived suppressor cells (MDSCs) while promoting T and NK cell activation

Svensson, Emma; Wenthe, Jessica; Milenova, I. Yoanna; Moreno, R. et al.

Part of Human Gene Therapy, 2015

LOAd703 and beyond: Advancing immunostimulatory gene therapy for cancer

Wenthe, Jessica

2022

• Download full text (pdf) of LOAd703 and beyond: Advancing immunostimulatory gene therapy for cancer

Safety of intratumoral immunostimulatory LOAd703 gene therapy in patients with advanced cancer

Irenaeus, Sandra; Wenthe, Jessica; Eriksson, Emma; Schiza, Aglaia et al.

Immunological evaluation of immunostimulatory gene therapy targeting CD40/4-1BB in advanced cancer patients (LOKON002)

Wenthe, Jessica; Eriksson, Emma; Naseri, Sedigheh; Sandin, Linda et al.

Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models

Wenthe, Jessica; Eriksson, Emma; Hellström, Ann-Charlotte; Moreno, Rafael et al.